Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Teriparatide
Drug ID BADD_D02166
Description Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used in the treatment of osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Indications and Usage For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
Marketing Status approved; investigational
ATC Code H05AA02
DrugBank ID DB06285
KEGG ID D06078
MeSH ID D019379
PubChem ID 16133850
TTD Drug ID D0YA2L
NDC Product Code 14403-0013; 41524-0010; 52221-119; 69766-088; 65129-1312; 0002-8400; 68594-030; 47781-652; 32861-0008
UNII 10T9CSU89I
Synonyms Teriparatide | hPTH (1-34) | Human Parathyroid Hormone (1-34) | Parathar | Teriparatide Acetate | Forteo
Chemical Information
Molecular Formula C181H291N55O51S2
CAS Registry Number 52232-67-4
SMILES CCC(C)C(C(=O)NC(CCC(=O)N)C(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(CC1=CNC=N1)C(=O)NC( CC(=O)N)C(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CC2=CNC=N2)C(=O)NC(CC(C)C)C( =O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CCSC)C(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)N C(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC3=CNC4=CC=CC=C43)C(=O)NC(CC(C)C)C(=O)NC(CCCNC (=N)N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O) O)C(=O)NC(C(C)C)C(=O)NC(CC5=CNC=N5)C(=O)NC(CC(=O)N)C(=O)NC(CC6=CC=CC=C6)C(=O)O)N C(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CO)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fatigue08.01.01.002--
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastrointestinal disorder07.11.01.001--Not Available
Gout15.01.06.001; 14.09.01.001--Not Available
Haemoglobin13.01.05.018--Not Available
Haemorrhoids24.10.02.002; 07.15.03.001--
Headache17.14.01.001--
Herpes zoster23.11.05.005; 17.09.03.026; 11.05.02.003--
Hiatus hernia22.09.02.004; 07.16.01.001--Not Available
Hypercalcaemia14.04.01.003; 05.04.01.002--
Hypercalciuria05.04.01.003; 20.02.01.007; 14.04.01.006--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hyperuricaemia14.09.01.003--
Hypotension24.06.03.002--
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
Injection site pain08.02.03.010; 12.07.03.011--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Loss of consciousness17.02.04.004--Not Available
Micturition urgency20.02.02.006--
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Neck pain15.03.04.009--
Nephrolithiasis20.04.01.002--
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages